Cingulate Inc. Common Stock CING

$4.72 +25.87% at last close
Market Cap$56.11 million
P/E Ratio—
Div Yield—
Volume1.63M
52-Week Range $3.16$11.89

Analyst Ratings

Consensus
Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
Avg. Price Target
$24.33 (+415.5% upside)

Full CING forecast & analyst actions →

Key Stats

Today's Range
$4.05 – $4.93
50-Day Range
$3.65 – $5.68
52-Week Range
$3.16 – $11.89
Volume
1.63 million shs
Average Volume
185K shs
Market Cap
$56.11 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.02%
Days to Cover
1.00

About Cingulate Inc. Common Stock

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
14
Exchange
XNAS
Listed
2021-12-08

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.